Paranta Biosciences is a clinical-stage biopharmaceutical company developing potentially transformative first-in-class biotherapeutics based on PB01, a unique form of recombinant human follistatin, targeting inflammatory, fibrotic and metabolic diseases with significant unmet medical need
Paranta is developing an inhaled form of PB01 for the treatment of CF lung disease. PB01 targets lung inflammation, fibrosis and mucus production and therefore has the potential to slow the progression of lung disease and preserve lung function in people living with CF. Despite the recent expansion in treatment options for CF with the introduction of medicines targeting specific CF mutations, there still remains a significant need for medicines which target the underlying lung inflammation and resulting lung remodelling.
Paranta is developing an injectable form of PB01 for use in the treatment of chronic kidney disease, including diabetic nephropathy. Kidney disease is a major comorbidity of diabetes affecting >150 million diabetic patients worldwide. Current treatment options for diabetic nephropathy, a form of chronic kidney disease, are only partially effective with limited ability to delay disease progression. Research conducted by McMaster University has shown the therapeutic potential of PB01 in a preclinical mouse model of diabetic kidney disease and fibrosis.
